title: Tranexamic acid: a potential adjunct to resectoscopic endometrial ablation.
abstract: Abnormal uterine bleeding (AUB) is a substantial cause of ill health in women worldwide. In this study, our aim was to evaluate the effectiveness of endometrial ablation using a modified urologic resectoscope along with tranexamic acid in AUB. Sixty patients were enrolled in this study. All patients underwent resectoscopic surgery. Patients were randomly divided into two groups. Group 1 (n = 30) received 500 mg of tranexamic acid. Group 2 (n = 30) served as the control group and underwent surgery without the administration of tranexamic acid. Total pictorial blood loss assessment chart (PBAC) scores were significantly lower postoperatively (152.14 ± 9.65 versus 6.6 ± 0.90; P < 0.001). When stratified by the administration of tranexamic acid, the number of patients with a postoperative day 1 PBAC score ≤15 was higher in the tranexamic group (19 versus 13), whereas the number of patients with a post operative day 1 PBAC score >15 was lower in the tranexamic group (11 versus 17), but the differences were not statistically significant (P > 0.05). AUB is a complex disease that may need repeated treatments. In expert hands, the treatment rate of resectoscopic surgery seems acceptable. However, some patients may require additional interventions, like repeated surgery, hysterectomy, or a drug therapy in the long run. Introduction of tranexamic acid as a potential adjunct to rollerball endometrial ablation may present an interesting option that requires additional well-designed studies before firm conclusions can be made.
authors.affiliation: 1 Department of Obstetrics and Gynecology, Istanbul University School of Medicine, Istanbul, Turkey.
authors.forename: Bulent
authors.initials: B
authors.lastname: Ergun
authors.forename: Ercan
authors.initials: E
authors.lastname: Bastu
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozsurmeli
authors.forename: Cem
authors.initials: C
authors.lastname: Celik
mesh_terms: D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D055356:Endometrial Ablation Techniques / Q000295:instrumentation / Q000379:methods*; D005260:Female; D006801:Humans; D015849:Plasminogen Inactivators / Q000627:therapeutic use*; D014148:Tranexamic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000628:therapy*
chemical_list: D015849:Plasminogen Inactivators; D014148:Tranexamic Acid